Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Second round of financing for Athenagen grosses $50mm

Executive Summary

Athenagen, which discovers small molecules for neurovascular conditions by beta-secretase inhibition or nicotinic acetylcholine receptor modulation, raised $50mm in its Series B financing. Returning investor Sanderling Ventures and new backer Clarus Venture co-led the round and were joined by new shareholder Index Ventures and current investors Charter Life Sciences and Astellas Venture Management. A representative from Clarus will take a seat on Athenagen's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies